Jump to content

Search the Community

Showing results for tags 'stampede trial'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


    • Announcements, meetings and other resources
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...

Date Created

  • Start


Last Updated

  • Start


Filter by number of...

Found 2 results

  1. This is a 7 minute video covering an Interview of Dr Neeraj Agarwal MD by Dr Farzanna S Haffizulla MD,FACP, FAMWA It was recorded in September 2017. It is on the Practice today Web Site. It compares Docetaxel with Abiraterone, Enzalutamide and Tak700 ( TAK-700 is sort of a cousin of abiraterone) which doesn't require concomitant use of prednisone). To see video click the link below. http://c.brightcove.com/services/mobile/streaming/index/rendition.m3u8?assetId=5547296943001&pubId=2421677169001&videoId=5469577148001
  2. The New Prostate Cancer Infolink reports Full data on ADT + chemotherapy from the STAMPEDE trial now published The report has links to the full text of articles in the Lancet regarding this research. "For men with metastatic prostate cancer starting [androgen deprivation] therapy for the first time, we found strong evidence to support the addition of docetaxel to androgen deprivation therapy as the new standard of care, and this combination should be offered to men who are fit to receive chemotherapy. " There is no sufficient evidence yet to recommend docetaxel plus androgen depriva
  • Create New...